On Tuesday, Ocular Therapeutix Inc (NASDAQ: OCUL) was 2.92% up from the session before settling in for the closing price of $10.27. A 52-week range for OCUL has been $2.00 – $11.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 121.20% over the past five years. When this article was written, the company’s average yearly earnings per share was at -16.50%. With a float of $134.99 million, this company’s outstanding shares have now reached $155.92 million.
Let’s look at the performance matrix of the company that is accounted for 267 employees. In terms of profitability, gross margin is 90.81%, operating margin of -187.94%, and the pretax margin is -227.16%.
Ocular Therapeutix Inc (OCUL) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Ocular Therapeutix Inc stocks. The insider ownership of Ocular Therapeutix Inc is 13.42%, while institutional ownership is 78.94%. The most recent insider transaction that took place on Oct 16 ’24, was worth 134,269. Before that another transaction happened on Aug 23 ’24, when Company’s Chief Strategy Officer sold 1,832 for $9.02, making the entire transaction worth $16,525. This insider now owns 176,194 shares in total.
Ocular Therapeutix Inc (OCUL) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -16.50% per share during the next fiscal year.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
You can see what Ocular Therapeutix Inc (OCUL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 16.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.35, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -1.01 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Ocular Therapeutix Inc (NASDAQ: OCUL) saw its 5-day average volume 0.9 million, a negative change from its year-to-date volume of 1.89 million. As of the previous 9 days, the stock’s Stochastic %D was 23.22%. Additionally, its Average True Range was 0.54.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 81.92%, which indicates a significant increase from 40.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.39% in the past 14 days, which was lower than the 59.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.58, while its 200-day Moving Average is $7.79. Nevertheless, the first resistance level for the watch stands at $10.80 in the near term. At $11.02, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.39. If the price goes on to break the first support level at $10.21, it is likely to go to the next support level at $9.84. Assuming the price breaks the second support level, the third support level stands at $9.62.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
There are 155,922K outstanding shares of the company, which has a market capitalization of 1.65 billion. As of now, sales total 58,440 K while income totals -80,740 K. Its latest quarter income was 16,440 K while its last quarter net income were -43,780 K.
